Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection
DOI: https://doi.org/10.2147/ijwh.s431520
2024-06-06
International Journal of Women s Health
Abstract:Giulia Marchetti, 1 Annika Taithongchai, 2 Dudley Robinson 2 1 Urogynaecology Department, Irmandade de Misericórdia da Santa Casa de São Paulo, Sao Paulo, Brazil; 2 Urogynaecology Department, King's College Hospital, London, UK Correspondence: Dudley Robinson, Email Vulvar vaginal atrophy is a common condition affecting postmenopausal women, significantly impacting their quality of life. Fortunately, various treatment options are available, ranging from hormonal to non-hormonal therapies. Ospemifene has emerged as a promising non-hormonal alternative for managing vulvar vaginal atrophy. Its targeted approach, unique mechanism of action, favorable safety profile particularly for breast tissue, and efficacy make it a valuable option for women seeking relief from symptoms such as vaginal pain, dryness and dyspareunia and cannot receive estrogen supplementations. This is particularly the case for breast cancer survivors or women with a significant family history of estrogen-dependent cancers. Hence, tailored treatment plans, considering individual preferences and health circumstances, are essential in optimizing outcomes and improving the overall well-being of affected individuals. Keywords: ospemifene, vulvovaginal atrophy, genitourinary syndrome of menopause, breast cancer, detrusor overactivity Physiological hypoestrogenism is responsible for the development of most climacteric symptoms related to menopause. Amongst the most bothersome is genitourinary syndrome of menopause (GSM), with symptoms such as dyspareunia, dysuria, vaginal dryness or pain and overactive bladder. 1,2 GSM has previously been called vulvar and vaginal atrophy (VVA), a common condition in postmenopausal women, characterized by thinning, drying, and inflammation of the vaginal walls and vulvar tissues due to decreased estrogen levels, triggering symptoms and impairing women's quality of life. 2 Treatment options aim to alleviate these symptoms and improve the vaginal environment. There are several lines of management available that can be divided into two large groups: hormonal therapies (systemic or local estrogens) and non-hormonal therapies (selective estrogen receptor modulators (SERMs) like ospemifene, lubricants, long-acting vaginal moisturizers, or laser therapy). Local estrogen therapy is the first-line treatment for VVA due to its targeted effectiveness and tissue specificity in providing symptomatic relief as well as restoring vaginal tissue health. 3,4 It involves the application of vaginal estrogen in the form of topical cream, a tablet or ring. However, it is well known that some patients cannot receive estrogen therapy or are averse to or poorly compliant with its use. For these women in whom estrogen-therapy is contraindicated, such as those with a history of breast cancer 3,4 or those having localized adverse effects, then non-estrogenic therapeutic options such as ospemifene are a promising medication. The other options such as vaginal moisturizers, vaginal lubricants and laser therapy are available as alternatives or adjuncts to treatment. Vaginal moisturizers are generally used for mild symptoms and are non-prescription, water-based vaginal preparations that can provide relief from vaginal dryness and discomfort. 3 Vaginal lubricants are used to reduce friction and discomfort during sexual intercourse. Unlike moisturizers, lubricants are typically used just before intercourse and can be water-based, silicone-based, or oil-based. Although both can help to alleviate VVA symptoms, they do not promote changes in the vaginal environment. 5 Fractional CO2 laser therapy or Erbium laser, also known as vaginal laser therapy, are a newer alternative treatment option. These involve the use of laser energy to stimulate collagen production, improve blood circulation, and rejuvenate vaginal tissues, reducing symptoms of VVA. 6 The choice of treatment depends on factors such as the severity of symptoms, overall health, medical history, and personal preferences. Studies, however, show that ospemifene has been proven to increase the vaginal maturation index, improve vulvar vestibular symptoms and effective in normalizing vulvar vestibular innervation sensitivity, 7,8 contributing to it being a promising choice among the group of non-hormonal treatments. Ospemifene belongs to a class of drugs known as selective estrogen receptor modulators (SERMs). It binds to estrogen receptors in the vaginal epithelium, promoting the restoration of vaginal tissue integrity, by improving vaginal maturation index and vaginal pH, 9,10 and is indicated for moderate-to-severe VVA symptoms. Common side effects may include hot flushes, vaginal discharge, muscle spasms, and sweating. 11 It is metabolize -Abstract Truncated-
obstetrics & gynecology